Efficacy of Cantharidin in Molluscum Contagiosum

Not Applicable

Completed

• Conditions: Molluscum Contagiosum, Skin Disease
• Interventions: Drug: cantharidin's vehicle; Drug: Cantharidin 0.7%

• Registration Number: NCT00667225
• Lead Sponsor: University of North Carolina, Chapel Hill

Brief Summary

The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-04-24
• Study First Submitted QC: 2008-04-25
• Study First Posted: 2008-04-28
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Results First Submitted: 2011-04-28
• Results First Submitted QC: 2011-04-28
• Status Verified: 2011-06
• Results First Posted: 2011-06-01
• Last Update Submitted: 2011-06-16
• Last Update Posted: 2011-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Anyone aged 5-10 years with the clinical diagnosis of molluscum contagiosum.

Read More

Exclusion Criteria

• Anyone with immunosuppression including HIV or previous organ transplantation.
• Anyone taking immunosuppressive medications.
• Anyone who has previously received treatment with cantharidin.
• Any female who has had her first menstrual period.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
I	cantharidin's vehicle	Subjects in this group will have topical application of cantharidin's vehicle at each visit.
II	Cantharidin 0.7%	Subjects in this group will have topical application of cantharidin at each visit.

Primary Outcome Measures

Name	Time	Method
Patients Experiencing Complete Clearance of All Molluscum Lesions.	Baseline compared to 8 weeks (5 visits)

Secondary Outcome Measures

Name	Time	Method
Mean Change in Each Group Measured by Lesion Count.	Baseline compared to 8 weeks (5 visits)	Average change in number of lesions from baseline to 8 weeks

Trial Locations

Locations (1)

University of North Carolina; 🇺🇸 Chapel Hill, North Carolina, United States